M
Marie Eve Boucher
Researcher at Institut Gustave Roussy
Publications - 4
Citations - 537
Marie Eve Boucher is an academic researcher from Institut Gustave Roussy. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 2, co-authored 4 publications receiving 387 citations.
Papers
More filters
Journal ArticleDOI
Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy
Roberto Ferrara,Laura Mezquita,M. Texier,J. Lahmar,Clarisse Audigier-Valette,Laurent Tessonnier,Julien Mazieres,Gérard Zalcman,Solenn Brosseau,Sylvestre Le Moulec,L. Leroy,Boris Duchemann,Corentin Lefebvre,Remi Veillon,Virginie Westeel,Serge Koscielny,Stéphane Champiat,Charles Ferté,David Planchard,Jordi Remon,Marie Eve Boucher,Anas Gazzah,Julien Adam,Emilio Bria,Giampaolo Tortora,Jean-Charles Soria,Benjamin Besse,Benjamin Besse,Caroline Caramella +28 more
TL;DR: It is suggested that HPD is more common with PD-1/PD-L1 inhibitors compared with chemotherapy in pretreated patients with NSCLC and is also associated with high metastatic burden and poor prognosis in patients treated with PD.
Journal ArticleDOI
Comparison of Fast-Progression, Hyperprogressive Disease, and Early Deaths in Advanced Non–Small-Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or Chemotherapy
Roberto Ferrara,Roberto Ferrara,Laura Mezquita,M. Texier,J. Lahmar,Clarisse Audigier-Valette,Laurent Tessonnier,Julien Mazieres,Gérard Zalcman,Solenn Brosseau,Sylvestre Le Moulec,Laura Leroy,Boris Duchemann,Corentin Lefebvre,Remi Veillon,Virginie Westeel,Serge Koscielny,Stéphane Champiat,Charles Ferté,David Planchard,Jordi Remon,Marie Eve Boucher,Anas Gazzah,Julien Adam,Giuseppe Lo Russo,Diego Signorelli,Marina Chiara Garassino,Jean C. Soria,Caroline Caramella,Benjamin Besse +29 more
TL;DR: PURPOSEHyperprogressive disease (HPD), fast progression (FP), and early death (ED) have been described in 13.8%, 4.7%, and 5.6% of patients with non-small-cell HPD, and in 5.1%, 2.8, and 6.4%, respectively, of patientswith non–small cell EMT in the past year.
Journal ArticleDOI
Baseline-derived neutrophil-to-lymphocyte ratio (dNLR) and lactate dehydrogenase (LDH) to predict the benefit of immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients.
Laura Mezquita,Edouard Auclin,Roberto Ferrara,Clarisse Audigier-Valette,Laurent Tessonnier,Melinda Charrier,Marie Eve Boucher,J. Lahmar,Caroline Caramella,Jordi Remon,David Planchard,Julien Adam,Anas Gazzah,Nathalie Chaput,Jean-Charles Soria,Benjamin Besse +15 more
TL;DR: This work tested if dNLR and LDH could have the same role in NSCLC patients and found that dNRL andLDH were recently correlated to ICI benefit in melanoma.
Journal ArticleDOI
Prevalence of autoimmune diseases in thymic epithelial tumors (TET) insights from RYTHMIC.
Jose Carlos Benitez,Marie Eve Boucher,Eric Dansin,Mallorie Kerjouan,Julien Mazieres,Eric Pichon,F. Thillays,Pierre-Emmanuel Falcoz,Benoit Roch,Youssef Oulkhouir,Calcagno Fabien,Luc Thiberville,Christelle Clément Duchene,Franck Morin,P. Missy,Pascal Thomas,Jean-Michel Maury,Thierry Jo Molina,Nicolas Girard,Benjamin Besse +19 more
TL;DR: This data indicates that TET are associated with autoimmune disorders (AID) in up to 30% of patients (pts) but there have been wide variations in the reported prevalence of AID in TET pts in small sin...